Show simple item record

dc.contributor.authorScemama, Pascal
dc.contributor.authorFarah, Fadi
dc.contributor.authorMann, Glen
dc.contributor.authorMargulis, Roman
dc.contributor.authorGritsenko, Karina
dc.contributor.authorShaparin, Naum
dc.date2022-08-11T08:08:09.000
dc.date.accessioned2022-08-23T15:44:31Z
dc.date.available2022-08-23T15:44:31Z
dc.date.issued2020-08-01
dc.date.submitted2020-09-22
dc.identifier.citation<p>Scemama P, Farah F, Mann G, Margulis R, Gritsenko K, Shaparin N. Considerations for Epidural Blood Patch and Other Postdural Puncture Headache Treatments in Patients with COVID-19. Pain Physician. 2020 Aug;23(4S):S305-S310. PMID: 32942790. <a href="https://www.painphysicianjournal.com/linkout?issn=&vol=23&page=S305" target="_blank" title="View article on publisher's site">View article on publisher's site</a></p>
dc.identifier.issn1533-3159 (Linking)
dc.identifier.pmid32942790
dc.identifier.urihttp://hdl.handle.net/20.500.14038/27331
dc.description.abstractBACKGROUND: A primary concern in the use of EBP in these patients is the possibility of seeding the virus in the CNS. Another important concern is related to the known hypercoagulable state in COVID-19 positive patients and associated organ dysfunction that may alter the metabolism of anticoagulants. The safety of the providers performing the EBP, the position of the patient and choices for image guidance (blind, fluoroscopic) are also key considerations to review. It is also important to explore the current state of knowledge about using allogenic instead of autologous blood as well as emerging techniques to eliminate the coronavirus from the blood. OBJECTIVES: In this article we pose the questions of how to manage PDPH in the COVID-19 positive patient and more specifically, the use of epidural blood patch (EBP). METHODS: Literature review. RESULTS: EBP is usually considered after the failure of conservative and pharmacological treatments. Because of the additional risks of EBP in COVID-19 patients it is important to also consider less traditional pharmacological treatments such as theophylinnes and cosyntropin that may offer some additional benefit for COVID-19 patient. Finally, other interventions other than EBP should also be considered including occipital nerve blocks, sphenopalatine ganglion blocks (infratemporal or transnasal). LIMITATIONS: A narrative review with paucity of literature. CONCLUSION: Going forward, an effective treatment for COVID-19 or a safe vaccine and a deeper understanding of the pathophysiology of the virus will certainly change the risk calculus involved in performing an EBP in a COVID-19 patient.
dc.language.isoen_US
dc.relation<p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=32942790&dopt=Abstract">Link to Article in PubMed</a></p>
dc.rightsCopyright the American Society of Interventional Pain Physicians under a Creative Commons license (CC-BY-NC), per publisher's open access statement at https://www.painphysicianjournal.com/journals/about.
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.subjectCOVID 19
dc.subjectPDPH
dc.subjectepidural blood patch
dc.subjectpost-dural puncture headache
dc.subjectAnesthesia and Analgesia
dc.subjectAnesthesiology
dc.subjectHealth Services Administration
dc.subjectInfectious Disease
dc.subjectNervous System Diseases
dc.subjectTherapeutics
dc.subjectVirus Diseases
dc.titleConsiderations for Epidural Blood Patch and Other Postdural Puncture Headache Treatments in Patients with COVID-19
dc.typeArticle
dc.source.journaltitlePain physician
dc.source.volume23
dc.source.issue4S
dc.identifier.legacyfulltexthttps://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=1120&amp;context=covid19&amp;unstamped=1
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/covid19/118
dc.identifier.contextkey19505260
refterms.dateFOA2022-08-23T15:44:31Z
html.description.abstract<p>BACKGROUND: A primary concern in the use of EBP in these patients is the possibility of seeding the virus in the CNS. Another important concern is related to the known hypercoagulable state in COVID-19 positive patients and associated organ dysfunction that may alter the metabolism of anticoagulants. The safety of the providers performing the EBP, the position of the patient and choices for image guidance (blind, fluoroscopic) are also key considerations to review. It is also important to explore the current state of knowledge about using allogenic instead of autologous blood as well as emerging techniques to eliminate the coronavirus from the blood.</p> <p>OBJECTIVES: In this article we pose the questions of how to manage PDPH in the COVID-19 positive patient and more specifically, the use of epidural blood patch (EBP).</p> <p>METHODS: Literature review.</p> <p>RESULTS: EBP is usually considered after the failure of conservative and pharmacological treatments. Because of the additional risks of EBP in COVID-19 patients it is important to also consider less traditional pharmacological treatments such as theophylinnes and cosyntropin that may offer some additional benefit for COVID-19 patient. Finally, other interventions other than EBP should also be considered including occipital nerve blocks, sphenopalatine ganglion blocks (infratemporal or transnasal).</p> <p>LIMITATIONS: A narrative review with paucity of literature.</p> <p>CONCLUSION: Going forward, an effective treatment for COVID-19 or a safe vaccine and a deeper understanding of the pathophysiology of the virus will certainly change the risk calculus involved in performing an EBP in a COVID-19 patient.</p>
dc.identifier.submissionpathcovid19/118
dc.contributor.departmentDepartment of Anesthesiology and Perioperative Medicine
dc.source.pagesS305-S310


Files in this item

Thumbnail
Name:
2020_23_S305_S310.pdf
Size:
108.2Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

Copyright the American Society of Interventional Pain Physicians under a Creative Commons license (CC-BY-NC), per publisher's open access statement at https://www.painphysicianjournal.com/journals/about.
Except where otherwise noted, this item's license is described as Copyright the American Society of Interventional Pain Physicians under a Creative Commons license (CC-BY-NC), per publisher's open access statement at https://www.painphysicianjournal.com/journals/about.